XORTX Therapeutics Inc. XRTX

Company Overview

XORTX Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for progressive kidney disease and related metabolic disorders. The company operates within the biotechnology and pharmaceutical industries, with a primary emphasis on treatments targeting dysregulated purine metabolism and elevated uric acid pathways. Its core development programs have historically centered on formulations of xanthine oxidase inhibitor therapies designed to address conditions such as autosomal dominant polycystic kidney disease (ADPKD), acute kidney injury, diabetic nephropathy, and other renal disorders where hyperuricemia may contribute to disease progression.

The company’s primary value drivers are its proprietary therapeutic programs, intellectual property portfolio, and clinical development activities rather than commercial product sales, as it remains a development-stage enterprise. XORTX has positioned itself around repurposed and reformulated pharmaceutical approaches intended to improve treatment outcomes in kidney disease populations with limited therapeutic options. The company was founded in Canada and later established a public market presence through listings in both Canada and the United States. Its evolution has largely involved advancing renal-focused drug candidates through preclinical and clinical development while seeking strategic financing and regulatory milestones.